A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis

Journal of Gastroenterology

Volumn 50, Issue 4, 2015, Pages 445-454

  Song, Do Seon ^a,b   Song, Myeong Jun ^a,b   Bae, Si Hyun ^a,b   Chung, Woo Jin ^a,c   Jang, Jae Young ^a,d   Kim, Young Seok ^a,d   Lee, Sae Hwan ^a,d   Park, Jun Yong ^a,e   Yim, Hyung Joon ^a,f   Cho, Sung Bum ^a,g   Park, Soo Young ^a,h   Yang, Jin Mo ^a,b  

^a Korean Liver Cancer Study Association   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Keimyung University School of Medicine   (South Korea)

^d Soonchunhyang University College of Medicine   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f Korea University   (South Korea)

^g Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^h Kyungpook National University Hospital   (South Korea)

Author keywords

Hepatic arterial infusion chemotherapy; Hepatocellular carcinoma; Portal vein tumor thrombosis; Sorafenib

Indexed keywords

ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; CISPLATIN; EPIRUBICIN; FLUOROURACIL; NICOTINAMIDE; SORAFENIB;

ADULT; AGED; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DISEASE COURSE; FEMALE; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTICENTER STUDY; PORTAL VEIN; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VENOUS THROMBOSIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CISPLATIN; DISEASE PROGRESSION; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRA-ARTERIAL; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PORTAL VEIN; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 84939885737     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-014-0978-3     Document Type: Article

References (29)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J cancer. 2010;127(12):2893–917 Epub 2011/02/26.
2. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130(7):417–22 Epub 2004/03/26.
3. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37(2):429–42 Epub 2003/01/24.
4. Pirisi M, Avellini C, Fabris C, Scott C, Bardus P, Soardo G, et al. Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study. J Cancer Res Clin Oncol. 1998;124(7):397–400 Epub 1998/08/27.
5. Villa E, Moles A, Ferretti I, Buttafoco P, Grottola A, Del Buono M, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors’ status in the tumor is the strongest prognostic factor for survival. Hepatology. 2000;32(2):233–8 Epub 2000/08/01.
6. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29(1):62–7 Epub 1998/12/24.
7. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2 Epub 2011/03/05.
8. EASL-EORTC. Clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43 Epub 2012/03/20.
9. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Intl. 2010;4(2):439–74 Epub 2010/09/10.
10. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34 Epub 2008/12/20.
11. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J of Med. 2008;359(4):378–90 Epub 2008/07/25.
12. Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, Lee do Y, et al. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer. 2007;110(1):129–37 Epub 2007/05/18.
13. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer. 2002;95(3):588–95 Epub 2002/09/05.
14. Kim HY, Kim JD, Bae SH, Park JY, Han KH, Woo HY, et al. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma. Korean J Hepatol. 2010;16(4):355–61 Epub 2011/03/19.
15. Eun JR, Lee HJ, Moon HJ, Kim TN, Kim JW, Chang JC. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. Scand J Gastroenterol. 2009;44(12):1477–86 Epub 2009/12/05.
16. Hiramine Y, Uto H, Imamura Y, Tabu K, Baba Y, Hiwaki T, et al. Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study. Exp Ther Med. 2011;2(3):433–41 Epub 2011/05/01.
17. Jeong SW, Jang JY, Lee JE, Lee SH, Kim SG, Cha SW, et al. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma. Asia Pac J Clin Oncol. 2012;8(2):164–71 Epub 2012/04/25.
18. Song do S, Bae SH. Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period. Clin Mol Hepatol. 2012;18(3):258–67 Epub 2012/10/24.
19. Korean Liver Cancer Study Group, National Cancer Center. Practice guidelines for managemeQuerynt of hepatocellular carcinoma 2009. Korean J. Hepatol. 2009;15(3):391–423. Epub 2009/09/29.
20. Woo HY, Bae SH, Park JY, Han KH, Chun HJ, Choi BG, et al. A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2010;65(2):373–82 Epub 2009/09/19.
21. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60 Epub 2010/02/23.
22. National Cancer Institute C. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Available from: URL: http://ctep.cancer.gov. Available from: http://ctep.cancer.gov.
23. Shao YY, Huang CC, Liang PC, Lin ZZ. Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma. Asia Pac J Clin Oncol. 2010;6(2):80–8 Epub 2010/06/23.
24. Lai YC, Shih CY, Jeng CM, Yang SS, Hu JT, Sung YC, et al. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol. 2003;9(12):2666–70 Epub 2003/12/12.
25. Song do S, Bae SH, Song MJ, Lee SW, Kim HY, Lee YJ, et al. Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol. 2013;19(29):4679–88 Epub 2013/08/08.
26. Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato S, et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2006;106(9):1990–7 Epub 2006/03/28.
27. Yau T, Chan P, Ng KK, Chok SH, Cheung TT, Fan ST, et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer. 2009;115(2):428–36 Epub 2008/12/25.
28. Nagano H, Wada H, Kobayashi S, Marubashi S, Eguchi H, Tanemura M, et al. Long-term outcome of combined interferon-alpha and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. Oncology. 2011;80(1–2):63–9 Epub 2011/06/11.
29. Park HC, Seong J, Tanaka M, Zeng ZC, Lim HY, Guan S, et al. Multidisciplinary management of nonresectable hepatocellular carcinoma. Oncology. 2011;81(Suppl 1):134–40 Epub 2012/01/11.